BioAge Labs vs HCW Biologics
BIOA and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIOA and HCWB compare
BioAge Labs is the larger company, worth 163 times as much as HCW Biologics ($240M against $1.5M).
HCW Biologics grew revenue faster over the last twelve months (700% versus 168% for BioAge Labs).
HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −912% at BioAge Labs.
BioAge Labs scores higher on the StockData Score (8 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIOA | HCWB |
|---|---|---|
| Size and price | ||
| Market cap | $240M | $1.5M |
| Share price | $5.22 | $0.800 |
| Change, 1 year | −32.4% | −94.6% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | 2.40 | 2.44 |
| Employees | 62 | – |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 23.1× | 0.2× (better) |
| P/B | 0.6× | 0.2× (better) |
| FCF yield | −36.8% | – |
| Fair value | – | $15.29 |
| Margin of safety | – | 94.8% |
| Growth | ||
| Revenue growth (TTM) | 168% | 700% (better) |
| Revenue growth, 5Y average | – | −57.9% |
| Profitability | ||
| Gross margin | – | 96.7% |
| Operating margin | −1026% | −115% (better) |
| Net margin | −912% | −83.8% (better) |
| FCF margin | −851% | – |
| Return on equity | −28.2% (better) | −151% |
| Return on invested capital | −283% | −70.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.88 (better) |
| Interest coverage | −378.2× | −14.0× (better) |
| Current ratio | 17.19 (better) | 0.06 |
| Altman Z-score | 5.27 (better) | −7.20 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.2% | 5.6% |
| Held by insiders | 21.9% | 34.9% |
| Insider net buying, 12 months | −$7.8M | $532K (better) |
| Short interest, % of float | 10.4% | 4.1% |
Go deeper
- BIOA stock overview
- BIOA income statement
- BIOA valuation and score
- HCWB stock overview
- HCWB income statement
- HCWB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.